sarilumab for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
REMAP-CAP sarilumab NCT02735707		RCT	sarilumab	standard of care	COVID-19 severe or critically	high	48/402	conclusif	demonstrated 76 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias suggested 86 % increase in clinical improvement (14-day) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis